The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Brigatinib in Japanese patients (pts) with ALK+ NSCLC: Final results from the phase 2 J-ALTA trial.
 
Pingkuan Zhang
Employment - Takeda
 
Toru Kumagai
Consulting or Advisory Role - AstraZeneca Japan; Nitto Denko; Takeda
Speakers' Bureau - AstraZeneca Japan; Bristol-Myers Squibb; Chugai Pharma; Lilly Japan; Merck Sharp & Dohme; Nippon Boehringer Ingelheim; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Amgen; AstraZeneca Japan; Chugai Pharma; Daiichi Sankyo; Eisai; Lilly Japan; Merck; Merck Sharp & Dohme; Nippon Boehringer Ingelheim; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda
Other Relationship - Pfizer (I)
 
Tatsuya Yoshida
Honoraria - Archer; AstraZeneca; Bristol-Myers Squibb Japan; Chugai/Roche; Lilly Japan; MSD Oncology; Nippon Boehringer Ingelheim; Novartis; Ono Pharmaceutical; Pfizer; Takeda
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Chugai/Roche; Lilly Japan; Novartis
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chugai/Roche (Inst); Chugai/Roche (Inst); Daiichi Sankyo (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Takeda (Inst)
 
Makoto Nishio
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Janssen; Lilly; Merck; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Janssen (Inst); Lilly (Inst); Merck (Inst); MSD (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Ryo Toyozawa
Honoraria - AstraZeneca; Chugai Pharma; Lilly Japan; MSD; Nippon Boehringer Ingelheim; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - Abbvie (Inst); Amgen (Inst); Daiichi Sankyo (Inst); Lilly Japan (Inst); Novartis (Inst); Pfizer (Inst); Takeda (Inst)
 
Takashi Seto
Employment - Precision Medicine Asia
Honoraria - Chugai Pharma; Covidien; Lilly Japan; Mochida Pharmaceutical Co. Ltd.; MSD; Novartis; Ono Pharmaceutical; Pfizer; Takeda; Towa Pharmaceutical
 
Kazuhiko Nakagawa
Honoraria - 3H Clinical Trial; Amgen; AstraZeneca Japan; Bayer Yakuhin; CareNet; Chugai Pharma; CMIC; CMIC Co., Ltd.; Japan Clinical Research Operations; Kyowa Kirin Co., Ltd.; Kyowa Kirin Co., Ltd.; Life Technologies; Lilly Japan; Medical Mobile Communications; Medical Review Co., Ltd.; Merck; MSD K.K; Neo Communication; Nikkei Business Publications, Inc; Nippon Boehringer Ingelheim; Nippon Boehringer Ingelheim; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Taiyo Pharma; Takeda; YODOSHA
Consulting or Advisory Role - Lilly Japan; Ono Pharmaceutical
Research Funding - Amgen (Inst); AstraZeneca Japan (Inst); Bayer Yakuhin (Inst); Bristol-Myers Squibb K.K. (Inst); Chugai Pharma (Inst); Covance (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EPS Holdings (Inst); EPS Holdings (Inst); EPS International (Inst); GlaxoSmithKline K.K. (Inst); IQvia (Inst); Janssen (Inst); Japan Clinical Research Operations (Inst); Kissei Pharmaceutical (Inst); Lilly Japan (Inst); Mebix (Inst); Medical Reserch Support (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); MSD K.K (Inst); Nippon Boehringer Ingelheim (Inst); Nippon Kayaku (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); PAREXEL International Corp. (Inst); PPD-SNBL (Inst); PRA HEALTHSCIENCES (Inst); Sanofi (Inst); SRL Diagnostics (Inst); SymBio Pharmaceuticals (Inst); Syneos Health (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
Patents, Royalties, Other Intellectual Property - Daiichi Sankyo Co., Ltd. (Inst)
 
Yuichiro Ohe
Honoraria - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Celltrion; Chugai Pharma; Kyorin; Kyowa Hakko Kirin; Lilly Japan; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Amgen; AstraZeneca; Celltrion; Chugai Pharma; Kyorin; Lilly Japan; Novartis; Ono Pharmaceutical; Takeda
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Ignyta (Inst); Janssen (Inst); Kissei Pharmaceutical (Inst); Kyorin (Inst); Lilly Japan (Inst); LOXO (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Nobuyuki Yamamoto
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; GlaxoSmithKline; Hisamitsu Pharmaceutical; Janssen; Janssen; Kyowa Kirin International; Lilly Japan; Merck; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Sanofi; Taiho Pharmaceutical; Takeda; Tsumura & Co.
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Lilly Japan; MSD; Novartis; Ono Pharmaceutical; Takeda; Thermo Fisher Scientific
Research Funding - Abbvie (Inst); Amgen (Inst); Asahi Kasei (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Janssen (Inst); Lilly (Inst); MSD (Inst); Nihonkayaku (Inst); Novartis (Inst); Sanofi (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); Tosoh Corporation (Inst); Tsumura & Co. (Inst)
 
Kentarou Kudou
Employment - Takeda
 
Takayuki Asato
Employment - Takeda
Stock and Other Ownership Interests - Chugai Pharma
 
Koichi Goto
Honoraria - Amgen; Amoy Diagnostics; AstraZeneca Japan; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb K.K.; Chugai Pharma; DAIICHI SANKYO Co., Ltd.; Eisai; Guardant Health; Janssen; Lilly Japan; Merck; Novartis; Ono Pharmaceutical; Otsuka; Takeda
Consulting or Advisory Role - Amgen; Bayer; Janssen; Lilly Japan; Medpace; Takeda
Research Funding - Amgen; AstraZeneca Japan; Boehringer Ingelheim; Bristol-Myers Squibb K.K.; Chugai Pharma; DAIICHI SANKYO Co., Ltd.; Eisai; Ignyta; Janssen; Kissei Pharmaceutical; Kyowa Kirin Co., Ltd.; Lilly Japan; Loxo; MEDICAL & BIOLOGICAL LABORATORIES CO., LTD.; Merck; Merus; MSD K.K.; NEC Corporation; Ono Pharmaceutical; Pfizer; Shanghai HaiHe Pharmaceutical; Spectrum Pharmaceuticals; Sumitomo Dainippon Pharma Co., Ltd.; Sysmex; Taiho Pharmaceutical; Takeda; Thermo Fisher Scientific; Turning Point Therapeutics